| Paul S. Herendeen |
Mr. Paul S. Herendeen is a Chief Financial Officer & Executive Vice President at Valeant Pharmaceuticals International, Inc., a Chief Financial Officer at Warner Chilcott Corp. and a Chief Financial Officer & Executive Vice President at Warner Chilcott Holdings Company III Ltd. Mr. Herendeen was previously employed as a Chief Financial Officer & Executive Vice President by Zoetis, Inc., a Chief Financial Officer & Executive Vice President by Warner Chilcott Ltd., a Chief Financial Officer, Director & Executive VP by Warner Chilcott Plc, a Chief Financial Officer & Executive Vice President by Carter-Wallace, Inc., a Chief Financial Officer & Executive Vice President by Warner Chilcott Plc /Old/ /Old/, and a Senior Auditor by Arthur Andersen LLP. He received his undergraduate degree from Boston College and an MBA from the University of Virginia Darden School of Business. |
| Scott Andrew Hirsch |
Mr. Scott A. Hirsch is Senior VP-Business Strategy & Communications at Valeant Pharmaceuticals International, Inc. and a Portfolio Manager at Surveyor Capital Ltd.
Mr. Hirsch was previously employed as Vice President by Plural Investments LLC, a Research Analyst by Credit Suisse First Boston (USA), Inc., and an Analyst by Credit Suisse First Boston (USA), Inc.
He received his undergraduate degree from the University of Pennsylvania, an undergraduate degree from Rhode Island School of Design, a graduate degree from the University of Pennsylvania and an MBA from the University of Pennsylvania.
|
| Joseph C. Papa |
Mr. Joseph C. Papa is a Chairman & Chief Executive Officer at Valeant Pharmaceuticals International, Inc., a President at Sergeant's Pet Care Products, Inc. and a President at Unico Holdings, Inc. Mr. Papa was previously employed as an Independent Non-Executive Director by Smith & Nephew A/S (Denmark), an Independent Non-Executive Director by Smith & Nephew Plc, a Chairman, President & Chief Executive Officer by The Perrigo Co., a Chairman & Chief Executive Officer by Perrigo Co. Plc, a Chairman-Pharmaceutical Segment by Cardinal Health, Inc., a President & Chief Operating Officer by Watson Pharmaceuticals, Inc., a President & Chief Operating Officer by DuPont Pharmaceuticals Co., a President-North American Global Country Operations by Pharmacia Corp., a President & Chief Operating Officer by Actavis Pharma, Inc., a President by G.D. Searle & Co., Inc., a Principal by Novartis AG, and a Vice President-Marketing by Novartis International AG. He also served on the board at The University of Connecticut Foundation, Inc. He received his undergraduate degree from the University of Connecticut and an MBA from Kellogg School of Management. |
| Tage Ramakrishna |
Dr. Tage Ramakrishna, MD, is a Chief Medical Officer, President-R&D at Valeant Pharmaceuticals International, Inc. Dr. Ramakrishna was previously employed as a Vice President-Clinical Research by Progenics Pharmaceuticals, Inc., a VP-International Drug Safety & Medical Affairs by ALTANA Pharma AG, and a Medical Director by Insmed, Inc. He received his undergraduate degree from Rutgers State University of New Jersey, a doctorate degree from Medical College of Virginia and a doctorate degree from Uniwersytet Medyczny IM Karola Marcinkowskiego. |
| Sam Eldessouky |
Mr. Sam Eldessouky is a Chief Accounting Officer, Senior VP & Controller at Valeant Pharmaceuticals International, Inc., a Chief Accounting Officer, Senior VP & Controller at Tyco International Ltd., a Member at Financial Executives International and a Member at The American Institute of Certified Public Accountants. Mr. Eldessouky was previously employed as a Chief Accounting Officer, Senior VP & Controller by Tyco International Plc. He received his undergraduate degree from Ain Shams University and a graduate degree from The University of Liverpool. |
| Louis W. Yu |
Dr. Louis W. Yu is a Chief Quality Officer at Valeant Pharmaceuticals International, Inc., a Senior Vice President-Quality & Compliance at Albany Molecular Research, Inc. and a Treasurer at Product Quality Research Institute. Dr. Yu was previously employed as a Senior VP-Global Quality & Compliance by Perrigo Co. Plc, a Senior VP-Global Quality & Compliance by The Perrigo Co., a Vice President-Quality by CV Therapeutics, Inc., a Global Head-Quality & Compliance by Forest Laboratories, Inc., and a Vice President-Quality & Compliance by Solvay Pharmaceuticals, Inc. He received his undergraduate degree from the University of Wisconsin, a graduate degree from Rutgers State University of New Jersey and a doctorate degree from Rutgers State University of New Jersey. |
| David Robert Hale |
Mr. David R. Hale is Partner at ValueAct Capital Management LP. He is on the Board of Directors at Valeant Pharmaceuticals International, Inc.
Prior to joining ValueAct Capital in January 2011, Mr. Hale was a Principal with The Parthenon Group, working in both the Boston and Mumbai offices of Parthenon’s strategic consulting practice, as well as in an investment role at Parthenon’s long-short public equity vehicle, Strategic Value Capital. He is a former director of MSCI, Inc.
He has an A.B., cum laude, from Dartmouth College
|
| Sarah B. Kavanagh |
Ms. Sarah B. Kavanagh is an Independent Director at Valeant Pharmaceuticals International, Inc., an Independent Director at HudBay Minerals, Inc., an Independent Trustee at WPT Industrial Real Estate Investment Trust and a Senior Manager-Public Relations at Harmonic, Inc. She is on the Board of Directors at Valeant Pharmaceuticals International, Inc., HudBay Minerals, Inc., WPT Industrial Real Estate Investment Trust, American Stock Transfer & Trust Co. LLC, Canadian Stock Transfer Co., Inc. and Canadian Tire Bank. Ms. Kavanagh was previously employed as a Commissioner by Ontario Securities Commission and a Vice Chairman by Scotia Capital, Inc. She also served on the board at Sustainable Development Technology Canada. She received her undergraduate degree from Williams College and an MBA from Harvard Business School. |
| Russel C. Robertson |
Mr. Russel C. Robertson is an Independent Director at Valeant Pharmaceuticals International, Inc., an Independent Director at Turquoise Hill Resources Ltd. and a Member at Institute of Corporate Directors. He is on the Board of Directors at Valeant Pharmaceuticals International, Inc., Turquoise Hill Resources Ltd. and BMO Nesbitt Burns Corp. Ltd. Mr. Robertson was previously employed as an Executive Vice President-Business Integration by Bank of Montreal, an EVP & Head-Anti-Money Laundering by BMO Financial Group, Inc., a Vice Chairman by Deloitte & Touche LLP, a Managing Partner by Arthur Andersen LLP /Canada/, and a Vice Chairman by BMO Financial Corp. He also served on the board at Virtus Investment Partners, Inc. He received his undergraduate degree from Richard Ivey School of Business. |
| Robert N. Power |
Mr. Robert N. Power is an Independent Director at Valeant Pharmaceuticals International, Inc. He is on the Board of Directors at Valeant Pharmaceuticals International, Inc. Mr. Power was previously employed as an Executive VP-Global Business Operations by Wyeth Corp. and a Managing Director-UK Region by Wyeth Pharmaceuticals, Inc. He also served on the board at Biovail Corp. He received his undergraduate degree from State University of New York College at Oneonta and a graduate degree from Medical College of Virginia. |
| Fernando Zarate |
Mr. Fernando Zarate is Vice President-Latin America at Valeant Pharmaceuticals International, Inc. |
| Argeris N. Karabelas |
Mr. Sam Eldessouky is a Chief Accounting Officer, Senior VP & Controller at Valeant Pharmaceuticals International, Inc., a Chief Accounting Officer, Senior VP & Controller at Tyco International Ltd., a Member at Financial Executives International and a Member at The American Institute of Certified Public Accountants. Mr. Eldessouky was previously employed as a Chief Accounting Officer, Senior VP & Controller by Tyco International Plc. He received his undergraduate degree from Ain Shams University and a graduate degree from The University of Liverpool. |
| John Alfred Paulson |
Mr. John A. Paulson is a President & Portfolio Manager at Paulson & Co., Inc. and a Principal at Paulson & Co., Inc. (Private Equity). He is on the Board of Directors at Valeant Pharmaceuticals International, Inc., 92nd Street Young Men's & Young Women's Hebrew Association, Council on Foreign Relations, Inc., Paulson European Opportunities Fund Ltd., The Partnership for New York City, Central Park Conservancy, Inc., The Economic Club of New York and The Metropolitan Museum of Art.
Prior to forming Paulson in 1994, he was a general partner of Gruss Partners and a managing director in mergers and acquisitions at Bear Stearns.
Mr. Paulson received his Masters of Business Administration with high distinction, as a Baker Scholar, from Harvard Business School in 1980. He graduated summa cum laude in Finance from New York University’s College of Business and Public Administration in 1978. |
| Fredric N. Eshelman |
Dr. Fredric N. Eshelman is a Director at Accelerator Corp. and Founder at Eshelman Ventures LLC. He is on the Board of Directors at The Medicines Co., Aton Pharma, Inc., G1 Therapeutics, Inc., Innocrin Pharmaceuticals, Inc., XORI Corp. and North Carolina School of Science & Mathematics.
Dr. Eshelman was previously employed as a Principal by Boehringer Mannheim Pharmaceuticals Corp., Founding Chairman by Furiex Pharmaceuticals, Inc., Senior Vice President & Director by Glaxo, Inc., Chief Executive Officer & Executive Chairman by Pharmaceutical Product Development LLC, and a Trustee by University of North Carolina at Wilmington.
He received his undergraduate degree from the University of North Carolina at Chapel Hill and a doctorate degree from the University of Cincinnati (Ohio). |
| Richard U. de Schutter |
Mr. Richard U. de Schutter is an Independent Director at Valeant Pharmaceuticals International, Inc. and an Owner at L.B. Gemini, Inc. He is on the Board of Directors at Valeant Pharmaceuticals International, Inc., Applied Silver, Inc., ING Americas, Inc. and Sprout Pharmaceuticals, Inc. Mr. de Schutter was previously employed as a Chairman by Durata Therapeutics, Inc., a Non-Executive Director by Ecolab, Inc., a Chairman by Incyte Corp., a Senior Independent Non-Executive Director by Smith & Nephew Plc, a Non-Executive Director by Varian, Inc., a Chairman, President & Chief Executive Officer by DuPont Pharmaceuticals Co., a Director & Chief Administrative Officer by Pharmacia Corp., a Vice Chairman & Chief Administrative Officer by Monsanto AG Co., a Chairman, President & Chief Executive Officer by G.D. Searle & Co., Inc., a Chairman & Chief Executive Officer by G.D. Searle & Co. Ltd., an Operating Partner by Linden Manager LLC, and a Non-Executive Director by Slate Pharmaceuticals, Inc. He also served on the board at Navicure, Inc., ActivBiotics, Inc. and MedPointe, Inc. He received his undergraduate degree from the University of Arizona and a graduate degree from the University of Arizona. |
| Amy B. Wechsler |
Dr. Amy B. Wechsler, MD, is an Independent Director at Valeant Pharmaceuticals International, Inc., a Member at American Academy of Child & Adolescent Psychiatry, a Member at American Academy of Dermatology, a Member at American Academy of Family Physicians, a Member at American Psychiatric Association, a Member at Independent Doctors of New York and a Member at The Skin Cancer Foundation. She is on the Board of Directors at Valeant Pharmaceuticals International, Inc. |
